Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Moderately to Severely Active Crohn's Disease
NCT04397263Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2020
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3 trial of guselkumab, sponsored by Janssen Pharmaceutical. Started Jun 2020; status: completed.
02
Drugs
guselkumab
Beyond the preview
Go deeper on NCT04397263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04397263.